Consider Endari for Patients on Hydroxyurea Who Still Have Sickle Cell Crises
Endari (en-DAH-ree, L-glutamine) is the first sickle cell treatment to be approved in almost 20 years.
Endari is for patients 5 years and older to reduce acute sickle cell complications...such as pain crises, acute chest syndrome, etc.
It's thought to work by reducing oxidative damage to "sickled" red blood cells. This may prevent the cells from adhering to blood vessels, causing thrombosis and reducing blood flow.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote